"Pioneering brain and mind clinic specialising in the diagnosis, treatment and ongoing care of individuals showing symptoms of cognitive impairment or mental health concerns"

During the past decade, RE:Cognition Health conducted 34 clinical trials. In the 10-year time frame, 34 clinical trials started and 16 clinical trials were completed, i.e. on average, 47.1% percent of trials that started reached the finish line to date. In the past 5 years, 16 clinical trials started and 14 clinical trials were completed. i.e. 87.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "RE:Cognition Health" #1 sponsor was "AstraZeneca" with 3 trials, followed by "Eli Lilly and Company" with 3 trials sponsored, "Hoffmann-La Roche" with 3 trials sponsored, "Novoic Limited" with 3 trials sponsored and "TauRx Therapeutics Ltd" with 3 trials sponsored. Other sponsors include 15 different institutions and companies that sponsored additional 18 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "RE:Cognition Health" #1 collaborator was "Eli Lilly and Company" with 3 trials as a collaborator, "ADIR, a Servier Group company" with 2 trials as a collaborator, "Anavex Australia Pty Ltd." with 2 trials as a collaborator, "Anavex Germany GmbH" with 2 trials as a collaborator and "AbbVie" with 1 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "RE:Cognition Health" are "Alzheimer Disease" (12 trials), "Alzheimer's Disease" (5 trials), "Alzheimer's Disease (Incl Subtypes)" (3 trials), "Migraine" (3 trials) and "Mild Cognitive Impairment" (3 trials). Many other conditions were trialed in "RE:Cognition Health" in a lesser frequency.

Most popular intervention types in "RE:Cognition Health" are "Drug" (32 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (19 trials), "Lanabecestat" (3 trials), "Lasmiditan" (3 trials), "ampreloxetine" (3 trials) and "BI 409306" (2 trials). Other intervention names were less common.

The vast majority of trials in "RE:Cognition Health" are 35 trials for "All" genders.

Currently, there are NaN active trials in "RE:Cognition Health". undefined are not yet recruiting, 7 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in RE:Cognition Health, undefined suspended trials, and 12 terminated clinical trials to date.

Out of the total trials that were conducted in RE:Cognition Health, 0 "Phase 1" clinical trials were conducted, 9 "Phase 2" clinical trials and 26 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".